Downregulation of glutathione S-transferase M1 protein in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis. 2014

Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
Department of Microbiology, Immunology and Biopharmaceuticals, College of Life Sciences, National Chiayi University, Chiayi, Taiwan.

Bladder cancer is highly recurrent following specific transurethral resection and intravesical chemotherapy, which has prompted continuing efforts to develop novel therapeutic agents and early-stage diagnostic tools. Specific changes in protein expression can provide a diagnostic marker. In our present study, we investigated changes in protein expression during urothelial carcinogenesis. The carcinogen BBN was used to induce mouse bladder tumor formation. Mouse bladder mucosa proteins were collected and analyzed by 2D electrophoresis from 6 to 20 weeks after commencing continuous BBN treatment. By histological examination, the connective layer of the submucosa showed gradual thickening and the number of submucosal capillaries gradually increased after BBN treatment. At 12-weeks after the start of BBN treatment, the urothelia became moderately dysplastic and tumors arose after 20-weeks of treatment. These induced bladder lesions included carcinoma in situ and connective tissue invasive cancer. In protein 2D analysis, the sequentially downregulated proteins from 6 to 20 weeks included GSTM1, L-lactate dehydrogenase B chain, keratin 8, keratin 18 and major urinary proteins 2 and 11/8. In contrast, the sequentially upregulated proteins identified were GSTO1, keratin 15 and myosin light polypeptide 6. Western blotting confirmed that GSTM1 and NQO-1 were decreased, while GSTO1 and Sp1 were increased, after BBN treatment. In human bladder cancer cells, 5-aza-2'-deoxycytidine increased the GSTM1 mRNA and protein expression. These data suggest that the downregulation of GSTM1 in the urothelia is a biomarker of bladder carcinogenesis and that this may be mediated by DNA CpG methylation.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009092 Mucous Membrane An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa. Lamina Propria,Mucosa,Mucosal Tissue,Muscularis Mucosae,Mucous Membranes,Membrane, Mucous,Membranes, Mucous,Mucosae, Muscularis,Mucosal Tissues,Propria, Lamina,Tissue, Mucosal,Tissues, Mucosal
D001743 Urinary Bladder A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION. Bladder,Bladder Detrusor Muscle,Detrusor Urinae,Bladder Detrusor Muscles,Bladder, Urinary,Detrusor Muscle, Bladder,Detrusor Muscles, Bladder
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D002085 Butylhydroxybutylnitrosamine A substituted carcinogenic nitrosamine. Butylbutanolnitrosamine,N-Butyl-N-(4-hydroxybutyl)nitrosamine,N-Nitroso-N-butyl-(4-hydroxybutyl)amine,N-Nitrosobutyl-4-hydroxybutylamine,N Nitrosobutyl 4 hydroxybutylamine
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004396 Coloring Agents Chemicals and substances that impart color including soluble dyes and insoluble pigments. They are used in INKS; PAINTS; and as INDICATORS AND REAGENTS. Coloring Agent,Dye,Dyes,Organic Pigment,Stain,Stains,Tissue Stain,Tissue Stains,Organic Pigments,Pigments, Inorganic,Agent, Coloring,Inorganic Pigments,Pigment, Organic,Pigments, Organic,Stain, Tissue,Stains, Tissue
D005260 Female Females

Related Publications

Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
January 1999, Urologia internationalis,
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
January 1993, Journal of cancer research and clinical oncology,
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
August 1987, Journal of the National Cancer Institute,
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
April 1988, Japanese journal of cancer research : Gann,
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
February 1977, Gan,
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
January 2024, Methods in molecular biology (Clifton, N.J.),
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
October 1981, Gan,
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
December 1987, Cancer research,
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
June 2000, Japanese journal of cancer research : Gann,
Jing-Jing Chuang, and Yuan-Chang Dai, and Yung-Lun Lin, and Yang-Yi Chen, and Wei-Han Lin, and Hong-Lin Chan, and Yi-Wen Liu
January 2018, Methods in molecular biology (Clifton, N.J.),
Copied contents to your clipboard!